- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02878733
Albumin Administration and Outcomes in Cardiac Surgery
Association Between Albumin Administration and Improved Survival and Organ Function in Adult Patients Undergoing Cardiac Surgery With Cardiopulmonary Bypass
Study Overview
Detailed Description
Following development of the study plan and project summary, approval was obtained (November 25th 2013) from the Duke University Medical Center institutional review board, who reviewed the study outline, including endpoints and treatment exposure groups prior to data extraction. HIPAA-compliant data were then extracted from the U.S. Cerner HealthFacts®, (Cerner Corp., Kansas City, MO) database. Patients who underwent cardiac surgery utilizing CPB between Jan 2001 and March 2013 were identified. In addition to hospital characteristics (bed-size, teaching status, location), encounter-level patient data (demographics, admission source, payer), comprehensive time-stamped medication orders, pharmacy records, laboratory results, admission and discharge diagnoses (International Classification of Diseases Ninth Revision Clinical Modification, ICD-9-CM codes) and procedures were available.
Study Population Adults that underwent isolated valve, isolated CABG or two or more procedures utilizing CPB, and who survived for at-least 24 hours were eligible for inclusion (except when CABG was performed emergently following a PCI). Procedures were identified using ICD-9-CM codes (39.61 = extracorporeal circulation auxiliary to open heart surgery) or CPT codes (indicating 'on-pump' surgery). Patients with missing or incomplete admission, procedure, and/or discharge dates, gender, and age were excluded. Discrete encounters less than four hours apart within the same hospital system, were considered contiguous. We also excluded those patients undergoing heart transplantation (ICD-9 procedure code 37.51) or with any of the following Elixhauser comorbidities: AIDS, lymphoma, metastatic cancer, solid tumors without metastases. Only the first operative procedure during this time was considered and patients undergoing multiple non-contiguous procedures were excluded.
Definition of Exposure The study cohort consisted of patients that had either received at least 500mL of any crystalloid (0.9% saline, buffered salt solutions such as Plasma-Lyte, Lactated Ringers etc.) with or without any volume of 5% albumin - the 'albumin' and 'crystalloid only' cohorts respectively. All intravenous fluids documented on the day of or the day following surgery were considered in order to determine eligibility for inclusion, and fluid volumes from the day of through two days following surgery were monitored. The investigators excluded crystalloids administered in smaller containers (<=250mL volume) as these were most likely to be used for medication delivery rather than for the maintenance of hydration or expansion of intravascular blood volume in this adult population. Such volume thresholds were not imposed for colloids in the 'albumin' cohort however. Patients were excluded from the study if they received any other colloid (e.g. albumin over 5% concentration or hydroxyethyl starch) or hypertonic saline. Patients were not excluded from the albumin arm if they received plasma protein fraction (PPF) however.
Definition of Outcomes The primary outcome was in-hospital mortality during the index admission in which cardiac surgery was performed. The investigators also examined in-hospital mortality within 30, 60, and 90 days after the index procedure. Secondary endpoints included major postoperative adverse cardiac, renal, hepatic, metabolic, pulmonary, neurologic, hematologic, or infectious events defined using clinical parameters or administrative codes (ICD-9-CM). Additional administrative secondary outcomes included: Length-of-stay, readmissions, and re-operations (return to operating room). MACE at 30, 60 and 90 days were calculated from four separate binary categories: 1) in-hospital mortality; 2) post-operative stroke or cerebrovascular accident per ICD-9 diagnosis codes not present-on-admission for the index visit or for subsequent visits within respective MACE timeframes; 3) post-operative revascularization or PCI; and 4) post-operative myocardial infarction. A composite binary indicator was also reported for any one or greater MACE condition met within the respective timeframes.
Study Type
Enrollment (Actual)
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Adults that underwent isolated valve, isolated CABG or two or more procedures utilizing CPB
Exclusion Criteria:
- death within 24 hours of index procedure
- patients undergoing heart transplantation
- Patients with missing or incomplete admission, procedure, and/or discharge dates, gender, and age were excluded
- patients with any of the following Elixhauser comorbidities: AIDS, lymphoma, metastatic cancer, solid tumors without metastases
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Albumin
patients that had received at least 500mL of any crystalloid (0.9% saline, buffered salt solutions such as Plasma-Lyte, Lactated Ringers etc.) with any volume of 5% albumin
|
patients that had either received any volume of 5% albumin in addition to at least 500mL of any crystalloid (0.9% saline, buffered salt solutions such as Plasma-Lyte, Lactated Ringers etc.)
|
Crystalloid Only
patients that had received at least 500mL of any crystalloid (0.9% saline, buffered salt solutions such as Plasma-Lyte, Lactated Ringers etc.) without any volume of 5% albumin
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
In-hospital mortality
Time Frame: any time point during index admission to hospital from post operative day (POD) 1 until discharge from hospital or POD 29
|
patients in either cohort who died during index admission to hospital at any time point from POD 0 until day of discharge or POD 29.
|
any time point during index admission to hospital from post operative day (POD) 1 until discharge from hospital or POD 29
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
30, 60, and 90 day mortality
Time Frame: 30, 60, and 90 days from POD 1
|
mortality rate for all patients in both cohorts at 30, 60, and 90 days from POD 0
|
30, 60, and 90 days from POD 1
|
Major Adverse Cardiac Events (MACE)
Time Frame: 30, 60, and 90 days from POD 0
|
MACE at 30, 60 and 90 days were calculated from four separate binary categories: 1) in-hospital mortality; 2) post-operative stroke or cerebrovascular accident per ICD-9 diagnosis codes not present-on-admission for the index visit or for subsequent visits within respective MACE timeframes; 3) post-operative revascularization or PCI; and 4) post-operative myocardial infarction.
|
30, 60, and 90 days from POD 0
|
Acute Kidney Injury
Time Frame: daily from POD 0 until discharge from hospital from index procedure, on average 14 days
|
Acute Kidney Injury Network (AKIN) serum creatinine (SCr) scores were calculated based on a combination of absolute SCr levels as well as relative SCr increases compared to baseline (greater numeric score indicates greater injury).
Baseline SCr was set as the most recent reading within a 30 day period prior to surgery.
In the case of lab values with exactly the same timestamp, the lowest SCr value was chosen.
In the case of missing or insufficient SCr data, patients were deemed unevaluable rather than assumed to have a normal SCr reading.
All AKIN scores are presented without respect to administration/non-administration of preoperative diuretics.
Quantitative urine output values, required for an AKIN urine evaluation component, were not captured in the database for any patient and therefore were not included.
The SCr criteria of AKIN were utilized, (which stages severity as 1, 2, or 3)
|
daily from POD 0 until discharge from hospital from index procedure, on average 14 days
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Adam kingeter, MD, Vanderbilt University Medical Center
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- Pro00050804
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Thoracic Surgery
-
Maquet Cardiopulmonary GmbHNAMSARecruitingCardiac Surgery | Cardiopulmonary Bypass | Thoracic Surgery | Vascular SurgerySpain
-
Vanderbilt UniversityEdwards LifesciencesCompletedCardiac Surgery | Thoracic Surgery | Heart Surgery | Heart Transplant
-
Academisch Medisch Centrum - Universiteit van Amsterdam...CompletedCardiac Surgery | Cardiopulmonary Bypass | Thoracic SurgeryNetherlands
-
Örebro University, SwedenRecruiting
-
Hospices Civils de LyonCompletedSurgery | ThoracicFrance
-
Hospital de Clinicas de Porto AlegreUNIVERSIDADE FEDERAL DO RIO GRANDE DO SUL (UFRGS)Completed
-
Universidade Federal de PernambucoReal Hospital Português de Beneficência em PernambucoCompleted
-
Universidade Federal de PernambucoUnknown
-
Hopital FochCompleted
-
Assaf-Harofeh Medical CenterUnknownThoracic Surgery
Clinical Trials on Albumin
-
Second Affiliated Hospital, School of Medicine,...Completed
-
University of Roma La SapienzaCompleted
-
Medical University of GrazActive, not recruitingDecompensated CirrhosisAustria
-
Baylor College of MedicineTerminatedSubarachnoid HemorrhageUnited States
-
Institut Paoli-CalmettesUnknownSolid Cancer in a Palliative Situation With AscitesFrance
-
Hainan People's HospitalSouthern Medical University, ChinaUnknown
-
Joachim ZdolsekRecruitingGynecologic Cancer | Colorectal Cancer | Colorectal Disorders | Urologic Cancer | Benign NeoplasmSweden
-
The First Hospital of Jilin UniversityCompleted
-
University of California, San DiegoGrifols Biologicals, LLCCompletedFluid Overload | Hypotension During Dialysis
-
Vanderbilt University Medical CenterCompletedCardiac DiseasesUnited States